|4/12/2021||Orion publishes Interim Report for January–March 2021 on Tuesday 27 April 2021|
|3/15/2021||Save the date – Orion’s Virtual Capital Markets Day on 26 May 2021 at 1.00 p.m. – 4.00 p.m. EEST|
|2/8/2021||Orion and Bayer expand development program for darolutamide in prostate cancer|
|1/20/2021||Orion publishes Financial Statement Release for 2020 on Tuesday 9 February 2021|
The Annual General Meeting of Orion Corporation was held on Thursday 25 March 2021 at Orion's Head Office in Espoo. The decisions and related material are available here.
|3/25/2021||Orion Corporation: Organising meeting of the Board of Directors|
|3/25/2021||Decisions taken by Orion Corporation’s Annual General Meeting on 25 March 2021|
|3/3/2021||Change to the Notice of Orion Corporation’s Annual General Meeting|
|3/2/2021||Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published|
Orion will publish Interim Report for January–March 2021 on Tuesday, 27 April 2021 approximately at 12.00 noon EEST. The release and related presentation material as well as link to the live webcast and teleconference details will be available here after publishing.
Orion Group's Financial Statement documents for 2020 are available here.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.